DUBLIN, Ohio—Atherion Bioresearch, Inc. (“Atherion” or the “Company”), a full-service Clinical Research Organization (“CRO”) company established by experienced drug development professionals and focused on helping its partners advance their pipelines, today announced the signing of a collaborative agreement with Strategic Patient Recruitment Solutions for Trials, LLC. (“SPRS”), a patient-recruitment focused CRO dedicated to ensuring patient engagement and enrollment in sponsored clinical trials. Through this agreement, the companies have entered into a non-exclusive partnership to offer their services to potential sponsors in either combination or individually and will refer potential clients to each other in order to offer an expanded suite of services to sponsors.

 

Atherion offers a wide array of drug development services and is differentiated from other CROs by its high level of engagement and industry experience. Atherion’s founding members are drug development professionals who have worked on the sponsor side to successfully advance drugs and complete trials and who have both private and public pharmaceutical/biotechnology experience. Atherion’s team knows the common pitfalls of outsourcing to CROs and strives instead to be a true partner in diagnostic and therapeutic pipeline advancement.

 

SPRS leadership brings decades of experience in clinical trials and CRO business development and a thorough understanding of the need for a high level of engagement to scale up and maintain patient involvement and recruitment into trials involving all disease indications. The combination of the experience and expertise of these two companies brings together a powerful platform of services to help sponsors with their drug development needs.

 

Michael Rosol, PhD, Chief Executive Officer of Atherion, said, “I am excited to announce this collaborative agreement with SPRS that will help amplify the reach and accelerate the growth of both of our companies.” Dr. Rosol continued, “Atherion has the experience in clinical trial operations and strategy and SPRS brings to the table deep expertise in patient-centric recruitment solutions. Together our two companies close the significant gaps sponsors currently face when running trials, whether outsourced or run internally, engagement and efficiency.”

 

Maria Frane, President of SPRS, said, “It’s really nice to collaborate with a CRO whose leadership have come from drug development sponsors.  They can truly put themselves in the shoes of our clients and  strive to provide the level of excellence they expect and deserve.  Together, we’ll break the mold of the traditional CRO and provide an innovative, practical and efficient approach to drug development and clinical trials.”

 

About Atherion

Atherion Bioresearch, Inc. is a hybrid Clinical Research Organization (“CRO”) and Drug Development (pharmaceutical) company. Atherion was established by a team of experienced drug development professionals dedicated to helping our partners advance their pipelines. Atherion is staffed by professionals who have been successful on the sponsor side; we know where the gaps are and what the need is. We offer full-service or bespoke clinical research services, enabling clients to develop their technology and grow their pipeline. Whether it be preclinical research from target or drug discovery to clinical research from First in Human to Phase IV, we are passionate about working with our partners to develop innovative medicines that will positively impact people's lives. On the drug development side, we are evaluating technologies for in-licensing to form a pipeline in the theranostic and therapeutic spaces for indications including cancer, where there are large unmet needs. For more information, please visit www.atherion-bioresearch.com.

 

About SPRS

Strategic Patient Recruitment Solutions (“SPRS”), LLC., is a clinical research services company focused on the critical need for patient recruitment into clinical trials. Studies have shown that 38.7% of terminated trials are due to slow enrollment, and 86% of trials fail to meet their enrollment timelines. Clinical trial sites are overburdened and understaffed. SPRS strives to understand the challenges each site faces and provides the support needed to recruit and enroll patients. Patients are often not in close proximity to a trial site or are not ambulatory. SPRS provides virtual and travel solutions to patients who can't get to the trial site. SPRS can also provide resources for research naive point of care sites. Through site support, decentralized solutions, public relations, marketing, and patient advocacy, SPRS plans for success and executes methods to effectively and efficiently enroll clinical trials. For more information, please visit www.sprsfortrials.com.

 

Forward-Looking Statements

This press release contains forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: uncertainty of future revenue and profitability; our ability to successfully complete research and development of our drug candidates; the timing, cost and uncertainty of obtaining regulatory approvals of our drug candidates; our ability to successfully commercialize our drug candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipated trends in our business; advances in technologies and development of new competitive products; the impact of the current coronavirus pandemic; and other risk factors. 

Potential investors are urged to consider statements that include the words “will,” “may,” “could,” “should,” “plan,” “continue,” “designed,” “goal,” “forecast,” “future,” “believe,” “intend,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this report. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements.

​